Given its involvement in many cancers, PRMT5 has become a promising target for therapeutic intervention and PRMT5 inhibitors are currently being tested in clinical trials for advanced solid tumors as well as myeloid leukemia and non-Hodgkin’s lymphoma24,25. This evidence concerns the gene PRMT5 and cancer.